MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvalsAug 5Quarterly updatefurosemide injection 80 mg/ 10 mlinsulin human
MannKind raises $50 million in private placement tied to Furoscix ReadyFlow approvalJul 24Financingfurosemide injection 80 mg/ 10 mlMannkind Corporation
MannKind registers Phase 2 trial of inhaled nintedanib for pulmonary fibrosisJul 1Trial updateMannkind Corporationnintedanib
